RobertMartinStrieterMD

Summary

• Dr. Strieter specializes in internal and pulmonary medicine. He was the Global Head of Translational Medicine for Respiratory Diseases at the Novartis Institutes for Biomedical Research. He is Professor Emeritus and former Professor and Chair, Department of Medicine, UVA School of Medicine, previous Professor and Chief of Pulmonary and Critical Care Medicine at UCLA, and previous Professor of Internal Medicine at the University of Michigan. His research has focused on inflammation/immunology related to pulmonary fibrosis, cancer, acute lung injury, lung transplantation, and adult progenitor cell biology. He is a member of the ASCI, AAP, and ATS. He is a Master of the ACP, a Fellow of the ACCP, a Fellow of the RCP-London, and Fellow of the AAAS. He holds ten patents, co-edited two books; and has published 89 book chapters and more than 570 peer-reviewed publications. His H-index is 131, and his work has been cited >50,000 times. He has received several scientific grants and awards, including NIH R01s, and Recognition for Scientific Accomplishments from the ATS. Thompson ISI In-Cites has listed him in the top 100 most cited scientists in Immunology (1992-2007); and he has been listed as one of 400 highly influential biomedical researchers (Eur J Clin Invest 2013; 43:1339-1365).
  
  In his previous role as Global Head, he oversaw discovery/profiling translational medicine experts (MDs) that performed early exploratory and profiling studies. In addition, he was Co-chair of the respiratory disease area decision board that directed and governed early drug development from the level of target/pathway evaluation to tool compound discovery/HTS to pharmacology/Med/Chem optimization to compound characterization to selection for proof of concept to first in human (Ph1a) to proof of concept studies in specific disease indications.
  
  In his current role, he is available for consultation relevant to early drug development with expertise related to innate and adaptive immunology.